Kalra Sanjay, Baruah Manash P, Niazi Asfandyar K
Bharti Hospital & BRIDE, Karnal, India.
Recent Pat Endocr Metab Immune Drug Discov. 2012 Jan;6(1):18-23. doi: 10.2174/187221412799015326.
Limitations of conventional human basal insulins like NPH have led to the development of more stable and peak less analogs. However, the first generation of basal analogs like glargine and detemir has certain shortcomings which do not allow them to be termed ideal basal insulins. Degludec, a novel basal insulin analog has the potential to overcome these limitations. This paper reviews the potential advantages of degludec over existing basal insulins and analogs. It discusses the basic and clinical studies performed on degludec so far, and highlights the possible role this molecule can play in the management of diabetes mellitus. In this paper, the recent patents on basal insulin have been reviewed so as to provide an insight into the advances in this field. In this article, we present a review of Degludec, as well as related patents.
常规人基础胰岛素（如中性鱼精蛋白锌胰岛素）的局限性促使了更稳定且峰值较小的类似物的研发。然而，第一代基础胰岛素类似物（如甘精胰岛素和地特胰岛素）存在某些缺点，这使得它们不能被称为理想的基础胰岛素。德谷胰岛素，一种新型基础胰岛素类似物，有潜力克服这些局限性。本文综述了德谷胰岛素相对于现有基础胰岛素和类似物的潜在优势。它讨论了迄今为止对德谷胰岛素进行的基础和临床研究，并强调了该分子在糖尿病管理中可能发挥的作用。在本文中，对基础胰岛素的近期专利进行了综述，以便深入了解该领域的进展。在本文中，我们对德谷胰岛素以及相关专利进行了综述。
